Stoke Therapeutics is the latest biotech company to debut on Wall Street, raising $142 million to test an experimental therapy for a rare form of epilepsy.
Stoke does not yet have any human data to show investors, but the Bedford, MA,... Read more »
Vice President for Research at UT Health Science Center at San Antonio
VP of Research and Special Initiatives, Google
Serial Entrepreneur and Investor
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Airbus, one of the world’s largest aircraft manufacturers, announced Monday it plans to ramp up production in coming decades with help from hologram-based virtual reality technology developed by Microsoft.
Netherlands-based Airbus says it will equip some of its aircraft and equipment... Read more »
Fiat Chrysler Automobiles has arguably been quieter on the autonomous vehicle front than Ford and GM, but this week marked a significant development for the company. FCA announced it will partner with Aurora, a Bay Area startup developing self-driving technologies.... Read more »
Academic researchers have long studied gender and racial disparities in STEM education, but they have not had widespread success in addressing these challenges. A University of Michigan professor and colleagues from 10 universities are hoping to change that.
At public research... Read more »
One of the entrants in the ultra-competitive race to develop treatments for the fatty liver disease known nonalcoholic steatohepatitis (NASH) suffered a setback in clinical testing today, but the company, Cymabay Therapeutics, still believes its drug could show promise as the... Read more »
[Updated 6/11/19, 7:31 am CT. See below.] Nick Mastronardi is finding success in countering the negative trend of endless partisan bickering by helping local governments gather public sentiments through online polling.
Every year, Detroit’s entrepreneurial community comes together for a five-day event encompassing panel discussions, TED talk-style keynote speeches, bootcamps, tech demos, and networking happy hours, all of which are open to the public and free upon registration.
Vertex Pharmaceuticals is committing $420 million in a pair of deals that expand the company’s research scope to experimental genetic treatments for two forms of muscular dystrophy.